Skip to main content
SpringerLink
Log in
Book cover

Recombinant Protein Drugs pp 89–106Cite as

Birkhäuser

Colony-stimulating factors: altering the practice of oncology

  • Chapter

  • 294 Accesses

Part of the book series: Milestones in Drug Therapy ((MDT))

Abstract

The process of haematopoiesis is regulated by a large number of glycoprotein cytokines which orchestrate the growth and development of haematopoietic cells, from the pluripotent self-renewing stem cell through committed lymphoid and myeloid progenitor and precursor cells to non-replicative, functionally mature blood cells. The control of haematopoiesis and the migration and functional activation of blood cells are closely controlled by stimulatory and inhibitory effects of at least 25 regulatory factors known as haematopoietic growth factors or cytokines.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Lieschke GJ, Burgess AW (1992) Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor.N Engl J Med327: 28–35

    Article  PubMed  CAS  Google Scholar 

  2. Lieschke GJ, Grail D, Hodgson G, Metcalf D, Stanley E, Cheers C, Fowler KJ, Basu S, Zhan YF, Dunn AR (1994) Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization.Blood73: 117–122

    Google Scholar 

  3. Lord BI, Bronchud MH, Owens S, Chang J, howell A, Souza L, Dexter TM (1989) The kinetics of human granulopoiesis following treatment with granulocyte colony-stimulating factorin vivo. Proc Natl Acad Sci USA86: 9499–9503

    Article  CAS  Google Scholar 

  4. Lord BI, Gurney H, Chang J, Thatcher N, Crowther D, Dexter TM (1992) Haemopoietic cell kinetics in humans treated with rGM-CSF.Int J Cancer50: 26–31

    Article  PubMed  CAS  Google Scholar 

  5. Spiekermann K, Roesler J, Emmendoerffer A, Elsner J, Welte K (1997) Functional features of neutrophils induced by G-CSF and GM-CSF treatment: differential effects and clinical implications.Leukemia11: 466–478

    Article  PubMed  CAS  Google Scholar 

  6. Molineux G, Dexter TM (1998) Biology of G-CSF. In: G Morstyn, TM Dexter, M Foote (eds):Filgrastim (r-metHuG-CSF) in clinical practice.Marcel Dekker, New York, Basel, Hong Kong, 1–39

    Google Scholar 

  7. Metcalf D (1986) The molecular biology and functions of the granulocyte-macrophage colony-stimulating factors.Blood67: 257–267

    PubMed  CAS  Google Scholar 

  8. Stanley E, Lieschke GJ, Grail D, Metcalf D, Hodgson G, Gall JA, Maher DW, Cebon J, Sinickas V, Dunn AR (1994) Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology.Proc Natl Acad Sci USA91: 5592–5596

    Article  PubMed  CAS  Google Scholar 

  9. Morstyn G, Lieschke GJ, Sheridan W, Layton J, Ceban J (1989) Pharmacology of the colony-stimulating factors.Trends Pharmacol10: 154–159

    Article  CAS  Google Scholar 

  10. Weisbart RH, Kwan L, Goldie DW, Gasson JC (1987) Human GM-CSF primes neutrophils for enhanced oxidative metabolism in response to the major physiological chemoattractants.Blood69: 18–21

    PubMed  CAS  Google Scholar 

  11. Wang JM, Colella S, Allavena P, Mantovani A (1987) Chemotactic activity of human recombinant granulocyte-macrophage colony-stimulating factor.Immunology138: 439–444

    CAS  Google Scholar 

  12. Aman MJ, Stockdreher K, Thews A, Kienast K, Aulitzky WE, Farber L, Haus U, Koci B, Huber C, Peschel C (1996) Regulation of immunomodulatory functions by granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factorin vivo. Ann Hematol73: 231–238

    Article  CAS  Google Scholar 

  13. Brossart P, Grünebach F, Stuhler G, Reichardt VL, Mohle R, Kanz L, Brugger W (1998) Generation of functional human dendritic cells from adherent peripheral blood monocytes by CD40 ligation in the absence of granulocyte-macrophage colony-stimulating factor.Blood11: 4238–4247

    Google Scholar 

  14. Labeur MS, Roters B, Pers B, Mehling A, Luger TA, Schwarz T, Grabbe S (1999) Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage.Jlmmunol162: 168–175

    CAS  Google Scholar 

  15. Dunussi-Joannopoulos K, Dranoff G, Weinstein HJ, Ferrara JLM, Bierer BE, Croop JM (1998) Gene immunotherapy in murinc acute myeloid leukemia: granulocyte-macrophage colony-stimulating factor tumor cell vaccines elicit more potent antitumor immunity compared with B7 family and other cytokine vaccines.Blood91: 222–230

    PubMed  CAS  Google Scholar 

  16. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D (1998) Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells.Nat Med4: 328–332

    Article  PubMed  CAS  Google Scholar 

  17. Molineux G, Pojda Z, Hampson IN, Lord BI, Dexter TM (1990) Transplantation potential of peripheral blood stem cells induced by granulocyte colony-stimulating factor.Blood76: 2153–2158

    PubMed  CAS  Google Scholar 

  18. Kiss JE, Rybka WB, Winklestein A, de Magalhoes Silverman M, Lister J, D’Andrea P, Ball ED (1997) Relationship of CD34+ cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation.Bone Marrow Transplant19: 303–310

    Article  PubMed  CAS  Google Scholar 

  19. Bodey GP, Buckley M, Sathe YS, Freireich EJ (1966) Quantitative relationships between circu-lating leukocytes and infection in patients with acute leukemia.Ann Intern Med64: 328–340

    PubMed  CAS  Google Scholar 

  20. Pizzo PA (1993) Management of fever in patients with cancer and treatement-induced neutropenia.N Engl J Med328: 1323–1332

    Article  PubMed  CAS  Google Scholar 

  21. DeVita VT Jr, (1997) Principles of cancer management: chemotherapy. In: VT Devita Jr, S Hellman, SA Rosenberg (eds):Cancer: principles and practice of oncology.Lippincott-Raven, Philadelphia 333–347

    Google Scholar 

  22. ASCO (1994) Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines.J Clin Oncol12: 2471–2508

    Google Scholar 

  23. Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, Kris M, Grous J, Picozzi V, Rausch G et at (1991) Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.N Engl J Med325: 164–170

    Article  PubMed  CAS  Google Scholar 

  24. Trillet-Lenoir V, Green J, Manegold C, Von Pawel J, Gatzemeier U, Lebeau B, Depierre A, Johnson P, Decostcr G, Tomita D et al (1993) Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy.Eur J Cancer29A: 319–324

    Article  PubMed  CAS  Google Scholar 

  25. Pettengell R, Gurney H, Radford JA, Deakin DP, James R, Wilkinson PM, Kane K, Bentley J, Crowther D (1992) Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin’s lymphoma: a randomized controlled trial.Blood80: 1430–1436

    PubMed  CAS  Google Scholar 

  26. Heil G, Hoelzer D, Sanz MA, Lechner K, Liu Yin JA, Papa G, Noens L, Szer J, Ganser A, O’Brien C et al (1997) A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults withde novoacute myeloid leukemia.Blood90: 4710–4718

    PubMed  CAS  Google Scholar 

  27. Weite K, Reiter A, Mempel K, Pfetsch M, Schwab G, Schrappe M, Riehm H (1996) A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia.Blood87: 3143–3150

    Google Scholar 

  28. de Graaf H, Willemse PHB, Bong SB (1996) Dose intensity of standard adjuvant CMF with granulocyte colony-stimulating factor for premenopausal patients with node-positive breast cancer.Oncology53: 289–294

    Article  PubMed  CAS  Google Scholar 

  29. Ribas A, Albanell J, Bellmunt J, Solé-Calvo L-A, Bermejo B, Gallardo E, Vidal R, Vera R, Eres N, Carulla J et al (1996) Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensity.J Clin Oncol14: 1573–1580

    PubMed  CAS  Google Scholar 

  30. Michon JM, Hartmann O, Bouffet E, Meresse V, Coze C, Rubie H, Bordigoni P, Cattiaux E, Ward N, Bemard JL et al (1998) An open-label, multicentre, randomised phase 2 study of recombinant human granulocyte colony-stimulating factor (filgrastim) as an adjunct to combination chemotherapy in paediatric patients with metastatic neuroblastoma.Eur J Cancer34: 1063–1069

    Article  PubMed  CAS  Google Scholar 

  31. Fukuoka M, Masuda N, Negoro S (1997) CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer.Brit J Cancer75: 307–309

    Article  Google Scholar 

  32. Splinter TA, Kranse R (1996) Randomized trial of chemotherapy +1— G-CSF without dose-intensification in small cell lung cancer (SCLC): improved survival in the G-CSF ann.Proc Am Soc Clin Oncol15: A993

    Google Scholar 

  33. Woll P, Hodgetts JLomax L, Bildet F, Cour-Chabemaud V, Thatcher N (1995) Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small cell lung cancer.J Clin Oncol13: 652–659

    PubMed  CAS  Google Scholar 

  34. Hartmann LC, Tschetter LK, Habermann TM, Ebbert LP, Johnson PS, Mailliard JA, Levitt R, Suman VJ, Witzig TE, Wieand HS et al Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia.N Engl J Med336: 1776–1780

    Article  Google Scholar 

  35. Hoelzer D (1997) Hematopoietic growth factors — not whether, but when and where.N Engl J Med336: 1822–1824

    Article  PubMed  CAS  Google Scholar 

  36. Silber JH, Fridman M, DiPaola RS, Haim Erder M, Pauly MV, Fox KR (1998) First cycle blood counts and subsequent neutropenia, dose reduction or delay in early stage breast cancer therapy../Clin Oncol16: 2392–2400

    CAS  Google Scholar 

  37. Silber JH, Fridman M, Shpilsky A, Even-Shoshan O, Smink DS, Jayaraman J, Fox KR, Pauly MV (1998) Modelling the cost effectiveness of granulocyte colony-stimulating factor use in early stage breast cancer.J Clin Oncol 16:2435–2444

    PubMed  CAS  Google Scholar 

  38. Gerhartz HH, Engelhard M, Meusers P, Brittinger G, Wilmanns W, Schlimok G, Mueller P, Huhn D, Musch R, Siegert W et al (1993) Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin’s lymphomas.Blood82: 2329–2339

    PubMed  CAS  Google Scholar 

  39. Yau JC, Neidhart JA, Triozzi P, Verma S, NemunaitisJQuick DP, Mayemik DG, Oette DH, Haynes FA, Holcenberg J (1996) Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating-factor support for dose-intensive cyclophosphamide, etoposide, and cisplatin.Amer J Hematol 51: 289–295

    Article  CAS  Google Scholar 

  40. Nemunaitis J (1997) A comparative review of colony-stimulating factors.Drugs54: 709–729

    Article  PubMed  CAS  Google Scholar 

  41. Lydaki E, Bolonaki E, Stíakaki E, Dimitriou H, Kalmantis T, Kalmanti M (1995) Efficacy of recombinant human granulocyte colony-stimulating factor and recombinant human granulocyte-macrophage colony-stimulating factor in neutropenic children with malignancies.Pediatr Hematol Oncol12: 551–558

    Article  PubMed  CAS  Google Scholar 

  42. Mamounas EP, Anderson S, Wickerham DL, Clark R, Stoller R, Hamm JT, Stewart J, Bear HD, Glass AG, Bornstein R et al (1994) The efficacy of recombinant human granulocyte colony-stimulating factor and recombinant human granulocyte macrophage colony-stimulating factor in permitting the administration of higher doses of cyclophosphamide in a doxorubicin-cyclophosphamide combination. An NSABP pilot study in patients with metastatic or high-risk primary breast cancer. National Surgical Adjuvant Breast and Bowel Project.Amer J Clin Oncol17: 374–381

    Article  CAS  Google Scholar 

  43. Godwin JE, Kopecky KJ, Head DR, Willman CL, Leith CP, Hynes HE, Balcerzak SP, Appelbaum FR (1998) A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031).Blood91: 3607–3615

    PubMed  CAS  Google Scholar 

  44. Rowe JM, Andersen JW, Mazza JJ, Bennett JM, Paietta E, Hayes FA, Oette D, Cassileth PA, Stadtmauer EA, Wiernik PH et al (1995) A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490).Blood86: 457–462

    PubMed  CAS  Google Scholar 

  45. Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman P, Lee EJ, Moore JO, Powell BL, Schiffer CA (1995) Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia.N Engl J Med332: 1671–1677

    Article  PubMed  CAS  Google Scholar 

  46. Löwenberg B, Suciu S, Archimbaud E, Ossenkoppele G, Verhoef GE, Vellenga E, Wijermans P, Berneman Z, Dekker AW, Stryckmans P et al (1997) Use of recombinant granulocyte-macrophage colony-stimulating factor during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia (AML): final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer (EORTC-LCG) and the Dutch Belgian Hemato-Oncology Cooperative Group (HOVON).Blood90: 2952–2961

    PubMed  Google Scholar 

  47. Heil G, Chadid L, Hoelzer D, Seipelt S, Mitrou P, Huber C, Kolbe K, Mertelsmann R, Lindemann A, Frisch J et al (1995) GM-CSF in a double-blind randomized, placebo controlled trial in therapy of adult patients withde novoacute myeloid leukemia (AML).Leukemia9: 3–9

    PubMed  CAS  Google Scholar 

  48. Rowe JM, Liesveld JL (1997) Hematopoietic growth factors in acute leukemia.Leukemia11: 328–341

    Article  PubMed  CAS  Google Scholar 

  49. Diehl V, Franklin J, Hasenclever D, Tesch H, Pfreundschuh M, Lathan B, Paulus U, Sieber M, Rueffer JU, Sextro M et al (1998) BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced stage Hodgkin’s lymphoma: interim report from a trial of the German Hodgkin’s Lymphoma Study Group.J Clin Oncol16: 3810–3821

    PubMed  CAS  Google Scholar 

  50. Stahel J, Jost LM, Cerny T, Pichert G, Honegger H, Tobler A, Jacky E, Fey M, Platzer E (1994) Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies.J Clin Oncol12: 1931–1938

    PubMed  CAS  Google Scholar 

  51. Gisselbrecht G, Prentice H, Bacigalupo A, Biron P, Milpied N, Rubie H, Cunningham D, Legros M, Pico JL, Linch DC et al (1994) Placebo-controlled phase III trial of lenograstim in bone-marrow transplantation.Lancet343: 696–700

    Article  PubMed  CAS  Google Scholar 

  52. Nemunaitis J, Rabinowe SN, Singer JW, Bierman DJ, Vose JM, Freedman AS, Onetto N, Gillis S, Oette D, Gold M et al (1991) Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer.N Engl J Med324: 1773–1778

    Article  PubMed  CAS  Google Scholar 

  53. Nemunaitis J, Rosenfeld CS, Ash R, Freedman MH, Deeg HJ, Appelbaum F, Singer JW, Flomenberg N, Dalton W, Elfenbein W et al (1995) Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation.Bone Marrow Transplant15: 949–954

    PubMed  CAS  Google Scholar 

  54. Bolwell BJ, Goormastic M, Yanssens T, Dannley R, Baucco P, Fishleder A (1994) Comparison of G-CSF with GM-CSF for mobilizing peripheral blood progenitor cells and for enhancing marrow recovery after autologous bone marrow transplant.Bone Marrow Transplant14: 913–918

    PubMed  CAS  Google Scholar 

  55. Schriber JR, Negrin RS, Chao NJ, Long GD, Homing SJ, Blume KG (1993) The efficacy of granulocyte colony-stimulating factor following autologous bone marrow transplantation for non-Hodgkin’s lymphoma with monoclonal antibody purged bone marrow.Leukemia7: 1491–1495

    PubMed  CAS  Google Scholar 

  56. Miggiano MC, Gherlinzoni F, Visani G, Belardinelli A, Ricci P, Rosti G, Mazza P, Motta MR, Rizzi S, Lemoli RM (1994) Hematological recovery after autologous bone marrow transplantation for high-grade non Hodgkin’s lymphomas: a single center experience.Haematologica79: 225–232

    PubMed  CAS  Google Scholar 

  57. Sheridan WP, Begley CG, Juttner CA, Szer J, To LB, Maher D, MaGrath KM, Morstyn G, Fox RM (1992) Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy.Lancet339: 640–644

    Article  PubMed  CAS  Google Scholar 

  58. Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A, Demuynck HMS, Link H, Zander A, Barge A et al (1996) Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantationversusautologous bone-marrow transplantation in lymphoma patients.Lancet347: 353–357

    Article  PubMed  CAS  Google Scholar 

  59. Smith TJ, Hillner BE, Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A, Link H, Zander A et al (1997) Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin’s and non-Hodgkin’s lymphoma.J Clin Oncol15: 5–10

    PubMed  CAS  Google Scholar 

  60. Ho AD, Young D, Maruyama M, Corringham RE, Mason JR, Thompson P, Grenier K, Law P, Terstappen LW, Lane T (1996) Pluripotent and lineage-committed CD34+ subsets in leukapheresis products mobilized by G-CSF, GM-CSF vs a combination of both.Exp Hematol14: 1460–1468

    Google Scholar 

  61. Lane TA, Law P, Maruyama M, Young D, Burgess J, Mullen M, Mealiffe M, Terstappen LW, Hardwick A, Moubayed M et al (1995) Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: potential role in allogeneic bone marrow transplantation.Blood85: 275–282

    PubMed  CAS  Google Scholar 

  62. Klumpp TR, Goldberg SL, Magdalinski AJ, Mangan KF (1997) Phase II study of high-dose cyclophosphamide, etoposide, and carboplatin (CEC) followed by autologous hematopoietic stem cell rescue in women with metastatic or high-risk non-metastatic breast cancer: multivariate analysis of factors affecting survival and engraftment.Bone Marrow Transplant20: 273–281

    Article  PubMed  CAS  Google Scholar 

  63. Van Hoef MEHM (1998) Haematological recovery after high-dose consolidation chemotherapy with peripheral blood progenitor cell rescue: the effects of the mobilization regimen and post-transplant growth factors.Neth J Med52: 30–39

    Article  PubMed  Google Scholar 

  64. Hohaus S, Martin H, Wassmann B, Egerer G, Haus U, Farber L, Burger KJ, Goldschmidt H, Hoelzer D, Haas R (1998) Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells.Bone Marrow Transplant22: 625–630

    Article  PubMed  CAS  Google Scholar 

  65. Demuynck H, Delforge M, Verhoef G, Zachée P, Vandenberghe P Boogaerts M (1995) A comparative study of peripheral blood progenitor cell collection in patients with multiple myeloma after single-dose cyclophosphamide combined with rhGM-CSF or rhG-CSF.Brit J Haematol90: 384–392

    Article  CAS  Google Scholar 

  66. Winter JN, Lazarus HM, Rademaker A, Villa M, Mangan C, Tallman M, Jahnke L, Gordon L, Newman S, Byrd K et al (1996) Phase I/II study of combined granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor administration for the mobilization of hematopoietic progenitor cells.J Clin Oncol14: 277–286

    PubMed  CAS  Google Scholar 

  67. Meisenberg B, Brehm T, Schmeckel A, Miller W, McMillan R (1998) A combination of low-dose cyclophosphamide and colony-stimulating factors is more cost-effective than granulocyte-colonystimulating factors alone in mobilizing peripheral blood stem and progenitor cells.Transfusion38: 209–215

    Article  PubMed  CAS  Google Scholar 

  68. Spitzer G, Adkins D, Mathews M, Velasquez W, Bowers C, Dunphy F, Kronmueller N, Niemeyer R, McIntyre W, Petruska P (1997) Randomized comparison of G-CSF + GM-CSF vs G-CSF alone for mobilization of peripheral blood stem cells: effects on hematopoietic recovery after high-dose chemotherapy.Bone Marrow Transplant20: 921–930

    Article  PubMed  CAS  Google Scholar 

  69. Schiodt I, Knudsen L, Jensen L, Nikolajsen K, Gaarsdal E, Johnsen HE (1998) Flow cytometry comparison of CD34+ subsets in bone marrow and peripheral blood after priming with glycosylated or non-glycosylated G-CSF.Bone Marrow Transplant21: 1167–1170

    Article  PubMed  CAS  Google Scholar 

  70. Watts M, Sullivan AM, Jamieson E, Pearce R, Fielding A, Devereux S, Goldstone AH, Linch DC (1997) Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: An analysis of progenitor-cell quantity and quality and factor predicting for these parameters in 101 pretreated patients with malignant lymphoma.J Clin Oncol15: 535–546

    PubMed  CAS  Google Scholar 

  71. Hoglund M, Smedmyr B, Bengtsson M, Tötterman TH, Cour-Chabernaud V, Yver A, Simonsson B (1997) Mobilization of CD34+ cells by glycosylated and non-glycosylated G-CSF in healthy volunteers — a comparative study.Eur J Haematol59: 177–183

    Article  PubMed  CAS  Google Scholar 

  72. Schmitz N, Bacigalupo A, Hasenclever D, Nagler A, Gluckman E, Clark P, Bourquelot P, Greinix H, Frickhofen N, Ringdén O et al (1998) Allogeneic hone marrow transplantation vs filgrastimmobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation.Bone Marrow Transplant21: 995–1003

    Article  PubMed  CAS  Google Scholar 

  73. Dale DC, Bonilla MA, Davis MW, Nakanishi AM, Hammond WP, Hurtzberg J, Wang W, Jakubowski A, Winton E, Lalezari P et al (1993) A randomized controlled phase III trial of recombinant human G-CSF for treatment of severe chronic neutropenia.Blood81: 2496–2502

    PubMed  CAS  Google Scholar 

  74. Welte K, Boxer LA (1997) Severe chronic neutropenia: Pathophysiology and Therapy.Semin Hematol34: 267–278

    PubMed  CAS  Google Scholar 

  75. Tidow N, Wette K (1997) Advances in understanding postreceptor signalling in response to granulocyte colony-stimulating factor.Curr Opin Hematol4: 171–175

    Article  PubMed  CAS  Google Scholar 

  76. Reiffers J, Cailliot C, Dazey B, Duchez I, Pigneux A, Cousin T, Bussi¨¨re Boiron JM (1998) Infusion of expanded CD34+ selected cells can abrogate post myeloablative chemotherapy neutropenia in patients with hematologic malignancies.Blood92: 126a

    Google Scholar 

  77. Johnston E, Crawford J, Lockbaum P, Shoemaker D, Bjurstrom A, Mallon K, Miller-Messana M, Schwab G (1998) Single-dose, subcutaneous (SC), sustained-duration filgrastim (SD)versusdaily filgrastim in non-small cell lung cancer patients (NSCLC): A randomized, controlled, dose-escalation study.Proc Amer Soc Oncol17: 73a

    Google Scholar 

  78. Miles S (1995) The use of hematopoietic growth factors in treating HIV infection.Curr Opin Hematol2: 227–233

    Article  PubMed  CAS  Google Scholar 

  79. Newman GW, Guarnaccia JR, Remold HG, Kazanjian PH Jr, (1997) Cytokines enhance neutrophils from human immunodeficiency virus-negative donors and AIDS patients to inhibit the growth ofMycobacterium avium in vitro. J Infect Dis175: 891–900

    CAS  Google Scholar 

  80. Kemper CA, Bermudez LE, Deresinski SC (1998) Immunomodulatory treatment ofMycobacterium aviumcomplex bacteremia in patients with AIDS by use of recombinant granulocyte-macrophage colony-stimulating factor.J Infect Dis177: 914–920

    Article  PubMed  CAS  Google Scholar 

  81. Barbaro G, Di Lorenzo G, Grisorio B, Soldini M, Barbarini G (1997) Effect of recombinant human granulocyte-macrophage colony-stimulating factor on HIV-related leukopenia: a randomized, controlled clinical study.AIDS11: 1453–1461

    Article  PubMed  CAS  Google Scholar 

  82. Frumkin-L-R (1997) Role of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the treatment of patients with HIV infection.Curr Opin Hematol4: 200–206

    Article  Google Scholar 

  83. Heymans P (1995) Haematopoietic growth factors as supportive therapy in HIV-infected patients.AIDS9: S9–S14

    Google Scholar 

  84. Crowe SM, Lopez A (1997) GM-CSF and its effects on replication of HIV-1 in cells of macrophage lineage.J Leukocyte Biol62: 41–48

    PubMed  CAS  Google Scholar 

  85. Wang J, Roderiquez G, Oravecz T, Norcross MA (1998) Cytokine regulation of human immunodeficiency virus type 1 entry and replication in human monocytes/macrophages through modulation of CCR5 expression.J Viral9: 7642–7647

    Google Scholar 

  86. Nimer SD, Leung DH, Wolin MJ, Golde DW (1994) Serum stem cell factor levels in patients with aplastic anemia.Int JHematol60: 185–189

    CAS  Google Scholar 

  87. Scopes J, Daly S, Atkinson R, Ball SE, Gordon-Smith Ecm Gibson FM (1996) Aplastic anemia: evidence for dysfunctional bone marrow progenitor cells and the corrective effect of granulocyte colony stimulating factor in vitro.Blood87: 3179–3185

    PubMed  CAS  Google Scholar 

  88. Bacigalupo A, Broccia G, Corda G, Arcese W, Carotenuto M, Gallamini A, Loctelli F, Mori PG, Sarcacco P, Todeschini G et al (1995) Antilymphocyte globulin, cyclosporin, and granulocyte colony-stimulating factor in patients with acquired severe aplastic anemia (SAA): a pilot study of the EBMT SAA Working Party.Blood85: 1348–1353

    PubMed  CAS  Google Scholar 

  89. Passweg JR, Tyndall A (1999) Autologous stem cell transplantation for autoimmune disease.Bone Marrow Transplant23: S35

    Google Scholar 

  90. Snowden JA, Biggs JC, Milliken ST, Fuller A, Staniforth D, Passuello F, Renwick J, Brooks PM (1998) A randomised, blinded, placebo-controlled, dose escalation study of the tolerability and efficacy of filgrastim for haemopoietic stem cell mobilisation in patients with severe active rheumatoid arthritis.Bone Marrow Transplant22: 1035–1041

    Article  PubMed  CAS  Google Scholar 

  91. Nasi ML, Lieberman PH, Lewis J, Prieto VG, Busam K, Williams L, Dantis L, Reyes S, Meyers ML, Livingston PO et al (1998) Intradermal (ID) injection of granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with metastatic melanoma.Proc Am Soc Clin Oncol17: 429a

    Google Scholar 

  92. Durek C, Schäfer I, Braasch H, Ulmer Ai, Ernst M, Had HD, Jocham D, Böhle A (1997) Effects of colony-stimulating factors on cellular cytotoxicity.Cancer Immunol Immunother44: 35–40

    Article  PubMed  CAS  Google Scholar 

  93. Baxevanis CN, Dedoussis GVZ, Papadopoulos NG, Missitzis I, Beroukas C, Stathopoulos GP, Papamichail M (1995) Enhanced human lymphokine-activated killer cell function after brief exposure to granulocyte-macrophage-colony stimulating factor.Cancer76: 1253–1260

    Article  PubMed  CAS  Google Scholar 

  94. Herrera C, García Pérez MJ, Ramirez R, Martín C, Alvarez MA, Martinez F, Gómez P, Garcia Castellano JM, Torres A (1997) Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells byin vitroincubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor.Bone Marrow Transplant19: 545–551

    Article  PubMed  CAS  Google Scholar 

  95. Dale DC, Liles WC, Llewellyn C, Rodger E, Price TH (1998) Neutrophil transfusions: kinetics and functions of neutrophile mobilized with granulocyte-colony-stimulating factor and dexamethasone.Transfusion38: 713–721

    Article  PubMed  CAS  Google Scholar 

  96. Adkins DR, Spitzer G, Johnston M, Velasquez W, Dunphy F, Petruska P (1997) Transfusions of granulocyte-colony-stimulating factor-mobilized granulocyte components to allogeneic transplant recipients: analysis of kinetics and factors determining posttransfusion neutrophil and platelet counts.Transfusion37: 737–748

    Article  PubMed  CAS  Google Scholar 

  97. Adkins DR, Brown RA, Goodnough LT, DiPersio JF (1998) Use of filgrastim (r-metHuG-CSF) in neutrophil transfusions. In: Morstyn G, Dexter TM, Foote M (eds):.Filgrastim (r-inetHuG-CSF) In clinical practice. New York, Basel, Hong Kong: Marcel Dekker, Inc., 149–164

    Google Scholar 

  98. Groopman JE, Molina J-M, Scadden DT (1989) Hematopoietic growth factors.N Engl J Med321: 1449–1459

    Article  PubMed  CAS  Google Scholar 

  99. Lieschke GJ, Cebon J, Morstyn G (1989) Characterization of the clinical effects after the first dose of bacterially synthesized recombinant human granulocyte-macrophage colony-stimulating factor.Blood74: 2634–2643

    PubMed  CAS  Google Scholar 

  100. Vial T, Descotes J (1995) Clinical toxicity of cytokines used as haemopoietic growth factors.Drug Safety13: 371–406

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Kinderklinik der Medizinischen Hochschule, Hannover, Germany

    Karl Welte

  2. Novuspharma, SpA, Monza, Italy

    Erich Platzer

Authors
  1. Karl Welte
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Erich Platzer
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Xantos Biomedicine, Fraunhoferstr. 22, Martinsried, D-82152, Germany

    Peter Buckel

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer Basel AG

About this chapter

Cite this chapter

Welte, K., Platzer, E. (2001). Colony-stimulating factors: altering the practice of oncology. In: Buckel, P. (eds) Recombinant Protein Drugs. Milestones in Drug Therapy. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-8346-7_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-0348-8346-7_4

  • Publisher Name: Birkhäuser, Basel

  • Print ISBN: 978-3-0348-9527-9

  • Online ISBN: 978-3-0348-8346-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation